21 Further results were reported at the 2019 American Society of Clinical Oncology Annual Meeting: the 2-year failure rate (defined as either relapse or persistent disease) was reduced numerically (HR 0.77, 95% CI 0.56–1.06), but did not reach statistical significance ( p =0.11). 69 There was a significantly reduced rate of incomplete tumor (R1 or R2) resection and reduced pathological staging.
1
0.1100
0.1100